Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019494429> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2019494429 endingPage "S25" @default.
- W2019494429 startingPage "S25" @default.
- W2019494429 abstract "Purpose: Expression of ACE2, a newly discovered member of the renin–angiotensin system, is increased in the ischaemic heart and atherosclerotic plaques in experimental models. The effect of CAD on circulating ACE2 levels in man is unknown. We hypothesised that ACE2 levels may increase in patients with CAD. Methods: 139 patients requiring coronary angiography for suspected CAD were recruited between 2008 and 2009. Blood was taken from the femoral artery, coronary artery ostium and the coronary sinus. Plasma ACE2 activity was measured using a quenched fluorescent substrate, and compared in those with angiographically normal coronary arteries (NCA, defined as <50% stenosis), and significant CAD (> 50% stenosis in ≥1 major epicardial vessel). Results: The mean ± SD age was 65 ± 10 years, body mass index 30 ± 6 kg/m2 and 70% were male. ACE2 activity was not significantly different between the three sites (P = 0.24). There was a significant main effect with ACE2 activity and CAD (P < 0.0001). ACE2 activity (geometric mean [25th, 75th interquartile range]) was higher in CAD compared to NCA at the femoral artery (25 [15,40] vs. 18 [12,25] pmol/min/ml, P = 0.016), coronary artery (22 [14,34] vs. 15 [11,23] pmol/min/ml, P = 0.009), and coronary sinus (23 [14,38] vs. 16 [10,24] pmol/min/ml, P = 0.007). These differences remained significant after adjusting for age and gender. Conclusion: Circulating ACE2 activity reflects the burden of coronary atherosclerosis with increased levels observed in those with angiographically proven CAD." @default.
- W2019494429 created "2016-06-24" @default.
- W2019494429 creator A5011333993 @default.
- W2019494429 creator A5015291161 @default.
- W2019494429 creator A5023760958 @default.
- W2019494429 creator A5035759710 @default.
- W2019494429 creator A5037167529 @default.
- W2019494429 creator A5044251783 @default.
- W2019494429 creator A5046509038 @default.
- W2019494429 creator A5066089436 @default.
- W2019494429 creator A5077991733 @default.
- W2019494429 creator A5080941710 @default.
- W2019494429 date "2011-01-01" @default.
- W2019494429 modified "2023-09-27" @default.
- W2019494429 title "Angiotensin Converting Enzyme (ACE) 2: A Novel Marker of Coronary Artery Disease (CAD) in Man" @default.
- W2019494429 doi "https://doi.org/10.1016/j.hlc.2011.05.065" @default.
- W2019494429 hasPublicationYear "2011" @default.
- W2019494429 type Work @default.
- W2019494429 sameAs 2019494429 @default.
- W2019494429 citedByCount "0" @default.
- W2019494429 crossrefType "journal-article" @default.
- W2019494429 hasAuthorship W2019494429A5011333993 @default.
- W2019494429 hasAuthorship W2019494429A5015291161 @default.
- W2019494429 hasAuthorship W2019494429A5023760958 @default.
- W2019494429 hasAuthorship W2019494429A5035759710 @default.
- W2019494429 hasAuthorship W2019494429A5037167529 @default.
- W2019494429 hasAuthorship W2019494429A5044251783 @default.
- W2019494429 hasAuthorship W2019494429A5046509038 @default.
- W2019494429 hasAuthorship W2019494429A5066089436 @default.
- W2019494429 hasAuthorship W2019494429A5077991733 @default.
- W2019494429 hasAuthorship W2019494429A5080941710 @default.
- W2019494429 hasBestOaLocation W20194944291 @default.
- W2019494429 hasConcept C119060515 @default.
- W2019494429 hasConcept C126322002 @default.
- W2019494429 hasConcept C164705383 @default.
- W2019494429 hasConcept C2775946041 @default.
- W2019494429 hasConcept C2776820930 @default.
- W2019494429 hasConcept C2778213512 @default.
- W2019494429 hasConcept C2778259205 @default.
- W2019494429 hasConcept C2778742706 @default.
- W2019494429 hasConcept C2778930955 @default.
- W2019494429 hasConcept C2779134260 @default.
- W2019494429 hasConcept C2780007028 @default.
- W2019494429 hasConcept C3008058167 @default.
- W2019494429 hasConcept C524204448 @default.
- W2019494429 hasConcept C71924100 @default.
- W2019494429 hasConceptScore W2019494429C119060515 @default.
- W2019494429 hasConceptScore W2019494429C126322002 @default.
- W2019494429 hasConceptScore W2019494429C164705383 @default.
- W2019494429 hasConceptScore W2019494429C2775946041 @default.
- W2019494429 hasConceptScore W2019494429C2776820930 @default.
- W2019494429 hasConceptScore W2019494429C2778213512 @default.
- W2019494429 hasConceptScore W2019494429C2778259205 @default.
- W2019494429 hasConceptScore W2019494429C2778742706 @default.
- W2019494429 hasConceptScore W2019494429C2778930955 @default.
- W2019494429 hasConceptScore W2019494429C2779134260 @default.
- W2019494429 hasConceptScore W2019494429C2780007028 @default.
- W2019494429 hasConceptScore W2019494429C3008058167 @default.
- W2019494429 hasConceptScore W2019494429C524204448 @default.
- W2019494429 hasConceptScore W2019494429C71924100 @default.
- W2019494429 hasLocation W20194944291 @default.
- W2019494429 hasOpenAccess W2019494429 @default.
- W2019494429 hasPrimaryLocation W20194944291 @default.
- W2019494429 hasRelatedWork W2053609302 @default.
- W2019494429 hasRelatedWork W2156510981 @default.
- W2019494429 hasRelatedWork W2319909300 @default.
- W2019494429 hasRelatedWork W2321301948 @default.
- W2019494429 hasRelatedWork W2351880569 @default.
- W2019494429 hasRelatedWork W2357426568 @default.
- W2019494429 hasRelatedWork W2362808561 @default.
- W2019494429 hasRelatedWork W2370528151 @default.
- W2019494429 hasRelatedWork W4220723560 @default.
- W2019494429 hasRelatedWork W4225827708 @default.
- W2019494429 hasVolume "20" @default.
- W2019494429 isParatext "false" @default.
- W2019494429 isRetracted "false" @default.
- W2019494429 magId "2019494429" @default.
- W2019494429 workType "article" @default.